PHASE I TRIAL OF SUNITINIB PLUS IMATINIB IN PATIENTS WITH METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)

被引：0
|
作者：
Lopez Pousa, A. [1 ]
Paz-Ares, L. [2 ]
Pericay, C. [3 ]
Garcia Del Muro, X. [4 ]
Flor, M. J. [5 ]
机构：
[1] Hosp Sta Creu & St Pau, Barcelona, Spain
[2] Hosp Virgen del Roc, Seville, Spain
[3] Corp Sanitaria Parc Tauli Inst Univ, Sabadell, Spain
[4] Inst Catala Oncol, Lhospitalet De Llobregat, Spain
[5] Hosp Virgen del Rocio, Oncol Serv, Seville, Spain
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：235 / 235
页数：1
相关论文
共 50 条
  • [1] A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study.
    Ryu, M.
    Park, S. H.
    Ryoo, B.
    Im, S.
    Kwon, H.
    Lee, S. S.
    Park, S. R.
    Kang, B. W.
    Kang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
    Y-K Kang
    C Yoo
    B-Y Ryoo
    J J Lee
    E Tan
    I Park
    J H Park
    Y J Choi
    J Jo
    J-S Ryu
    M-H Ryu
    British Journal of Cancer, 2013, 109 : 2309 - 2315
  • [3] Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
    Kang, Y-K
    Yoo, C.
    Ryoo, B-Y
    Lee, J. J.
    Tan, E.
    Park, I.
    Park, J. H.
    Choi, Y. J.
    Jo, J.
    Ryu, J-S
    Ryu, M-H
    BRITISH JOURNAL OF CANCER, 2013, 109 (09) : 2309 - 2315
  • [4] Phase I trial of panobinostat (P) and imatinib (IM) in patients with treatment-refractory gastrointestinal stromal tumors (GIST).
    Bauer, Sebastian
    Hilger, Ralf A.
    Grabellus, Florian
    Nagarajah, James
    Hoiczyk, Mathias
    Reichardt, Annette
    Ahrens, Marit
    Pink, Daniel
    Muehlenberg, Thomas
    Scheulen, Max E.
    Schuler, Martin H.
    Reichardt, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] RANDOMIZED PHASE 3 TRIAL OF REGORAFENIB IN PATIENTS (PATIENTS) WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMOR (GIST) PROGRESSING DESPITE PRIOR TREATMENT WITH AT LEAST IMATINIB (IM) AND SUNITINIB (SU) : GRID TRIAL.
    Nishida, T.
    Casali, P. G.
    Reichardt, P.
    Kang, Y. -K.
    Blay, J. -Y.
    Joensuu, H.
    Maki, R. G.
    Rutkowski, P.
    Hohenberger, P.
    Gelderblom, H.
    Leahy, M. G.
    von Mehren, M.
    Schoffski, P.
    Blackstein, M. E.
    Cesne, A. L.
    Badalamenti, G.
    Xu, J. -M.
    Laurent, D.
    Kuss, I.
    Demetri, G. D.
    ANNALS OF ONCOLOGY, 2012, 23 : 20 - 20
  • [6] Randomized phase 3 trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU) - GRID trial
    Reichardt, P.
    Demetri, G.
    Kang, Y-K
    Blay, J-Y
    Joensuu, H.
    Maki, R.
    Rutkowski, P.
    Hohenberger, P.
    Gelderblom, H.
    Leahy, M.
    von Mehren, M.
    Schoffski, P.
    Blackstein, M.
    Le Cesne, A.
    Badalamenti, G.
    Xu, J.
    Nishida, T.
    Laurent, D.
    Kuss, I
    Casali, P.
    ONKOLOGIE, 2012, 35 : 168 - 168
  • [7] Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial
    Casali, P. G.
    Reichardt, P.
    Kang, Y.
    Blay, J.
    Joensuu, H.
    Maki, R. G.
    Rutkowski, P.
    Hohenberger, P.
    Gelderblom, H.
    Leahy, M. G.
    von Mehren, M.
    Schoffski, P.
    Blackstein, M. E.
    Le Cesne, A.
    Badalamenti, G.
    Xu, J.
    Nishida, T.
    Laurent, D.
    Kuss, I.
    Demetri, G. D.
    ANNALS OF ONCOLOGY, 2015, 26 : 29 - 29
  • [8] Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.
    Demetri, George D.
    Reichardt, Peter
    Kang, Yoon-Koo
    Blay, Jean-Yves
    Joensuu, Heikki
    Maki, Robert G.
    Rutkowski, Piotr
    Hohenberger, Peter
    Gelderblom, Hans
    Leahy, Michael Gordon
    von Mehren, Margaret
    Schoffski, Patrick
    Blackstein, Martin E.
    Le Cesne, Axel
    Badalamenti, Giuseppe
    Xu, Jian-Ming
    Nishida, Toshirou
    Laurent, Dirk
    Kuss, Iris
    Casali, Paolo Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Surgical resection after imatinib treatment in patients with metastatic or unresectable gastrointestinal stromal tumors
    Ryu, Min-Hee
    Lee, Jae-Lyun
    Chang, Heung Moon
    Kim, Tae Won
    Kim, Hee Cheol
    Yook, Jeong Hwan
    Yu, Chang Sik
    Kim, Byung Sik
    Kim, Jin Cheon
    Kang, Yoon-Koo
    ANNALS OF ONCOLOGY, 2006, 17 : 164 - 164
  • [10] A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors ( GIST) following failure of at least imatinib and sunitinib
    Ganjoo, K. N.
    Villalobos, V. M.
    Kamaya, A.
    Fisher, G. A.
    Butrynski, J. E.
    Morgan, J. A.
    Wagner, A. J.
    D'Adamo, D.
    McMillan, A.
    Demetri, G. D.
    George, S.
    ANNALS OF ONCOLOGY, 2014, 25 (01) : 236 - 240
12345